Stroke Prevention in Atrial Fibrillation


Despite the evidence-based guidelines for the management of atrial fibrillation (AF), serious gaps continue to exist between clinical knowledge and practice, leaving patients at risk for disabling strokes. It is estimated that up to 67% of AF-related strokes are preventable. The significant increase in mortality and functional impairment is even more alarming, compared to non-AF strokes.


Updated AF treatment guidelines recommend new oral anticoagulants (NOACs) over warfarin for stroke prevention except, in patients with moderate to severe mitral stenosis or a mechanical heart valve. Based on some recent trials, NOACs were superior to warfarin for the prevention of the composite of stroke and systemic embolism in patients with AF and an additional risk factor for stroke. Reversal agents are now also available for NOACs in patients for severe bleeding or emergency procedures.


With the increased utilization of NOACs, it is critical for the clinician to understand the clinical and practical usage of these agents in diverse patient populations and clinical situations.

Close X
Other videos you might like

Recent Videos


LAAOS III: Surgical AFIB Ablation Evaluation
Richard Whitlock


Implantable Cardiac Monitoring
Jan Steffel


AHA 2020: The VITAL-AF Trial


Ensuring Its Value: Validated Cost Effectiveness of Medtronic Reveal LINQ
Klaus Witte, Matthew Reynolds, Paul Guyler


Emerging Clinical Evidence on Left Atrial Appendage Closure: A Case-based…
Ignacio Cruz, Jens Erik Nielsen-Kudsk, Prof Henning Ebelt


New Stroke Outcomes Data: The Role of Prolonged Cardiac Monitoring in…
Wolfram Döhner, Georgios Tsivgoulis, Robert Hatala
Testosterone and the Heart

European Cardiology Review 2019;14(2):103–10

Hypertension and Stroke: Update on Treatment

European Cardiology Review 2019;14(2):111–5


European Cardiology 2012;8(3):150

Clinical Implications from Recent Trials and New Guidelines for Stroke Prevention in Atrial Fibrillation

European Cardiology 2012;8(3):174-8

Stroke Prevention in Atrial Fibrillation

European Cardiovascular Disease 2006;2(1):98–9